182 related articles for article (PubMed ID: 25735254)
1. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).
Kushnir CL; Angarita AM; Havrilesky LJ; Thompson S; Spahlinger D; Sinno AK; Tanner EJ; Secord AA; Roche KL; Stone RL; Fader AN
Gynecol Oncol; 2015 Jun; 137(3):503-7. PubMed ID: 25735254
[TBL] [Abstract][Full Text] [Related]
2. Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.
Dioun SM; Vilardo N; Goldberg GL; Gressel GM
Gynecol Oncol; 2019 Nov; 155(2):301-304. PubMed ID: 31575390
[TBL] [Abstract][Full Text] [Related]
3. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
4. Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?
Gill SE; Savage K; Wysham WZ; Blackhurst DW; Winter WE; Puls LE
Gynecol Oncol; 2013 Jun; 129(3):544-7. PubMed ID: 23523653
[TBL] [Abstract][Full Text] [Related]
5. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.
Blank N; Laskov I; Kessous R; Kogan L; Lau S; Sebag IA; Gotlieb WH; Rudski L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):737-743. PubMed ID: 28801766
[TBL] [Abstract][Full Text] [Related]
6. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies.
Kesterson JP; Odunsi K; Lele S
Chemotherapy; 2010; 56(2):108-11. PubMed ID: 20407236
[TBL] [Abstract][Full Text] [Related]
7. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
[TBL] [Abstract][Full Text] [Related]
8. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
Grenader T; Goldberg A; Gabizon A
Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Li Y; Finkel KW; Hu W; Fu S; Liu J; Coleman R; Kavanagh JJ
Gynecol Oncol; 2007 Aug; 106(2):375-80. PubMed ID: 17512575
[TBL] [Abstract][Full Text] [Related]
10. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
11. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
Kim RJ; Peterson G; Kulp B; Zanotti KM; Markman M
Gynecol Oncol; 2005 May; 97(2):374-8. PubMed ID: 15863132
[TBL] [Abstract][Full Text] [Related]
12. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
13. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
14. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
15. Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer.
Yildirim Y; Gultekin E; Avci ME; Inal MM; Yunus S; Tinar S
Int J Gynecol Cancer; 2008; 18(2):223-7. PubMed ID: 17511800
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
